Company Profile
Quoin Stock Price, News & Catalysts
- Ticker:
- QNRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.89 USD (+10.09%)
Close
Last updated: August 12, 2026
9.16M USD
Market cap
Why the stock is moving
As of Aug 12, 2026, QNRX closed up 10.1% at $5.89. No new same-company headline was identified in the current news window.
Company overview
Rare Dermatology
Quoin Pharmaceuticals develops therapies for rare and orphan dermatologic diseases. Its lead program addresses the defective skin barrier and severe inflammation associated with Netherton syndrome.
QRX003
QRX003 is a topical lotion containing a serine-protease inhibitor. It is in Phase 3 development as a potential first approved treatment specifically for Netherton syndrome.
Global Regulatory Strategy
Quoin is pursuing development and regulatory pathways in the United States, Japan and Saudi Arabia, supported by Fast Track, orphan-drug and rare-pediatric-disease designations.
Future catalysts
- Completion of Phase 3 recruitment for QRX003 by the end of 2026.
- Potential NDA submission for QRX003 in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Quoin (QNRX)?
Quoin (QNRX) most recently closed at 5.89 USD, a +10.09% move versus the previous session.
What is the market cap of Quoin (QNRX)?
Quoin currently has a market capitalization of 9.16M USD on BioPharmSignal.
What does Quoin do?
Rare Dermatology Quoin Pharmaceuticals develops therapies for rare and orphan dermatologic diseases. Its lead program addresses the defective skin barrier and severe inflammation associated with Netherton syndrome. QRX003 QRX003 is a topical lotion containing a serine-protease inhibitor. It is in Phase 3 development as a potential first approved treatment...
On which exchange is QNRX stock listed?
Quoin (QNRX) is associated with NASDAQ, United States, Biopharma.
What is Rare?
Rare Dermatology Quoin Pharmaceuticals develops therapies for rare and orphan dermatologic diseases.
Which conditions is Quoin targeting with Rare?
Quoin is associated with inflammatory disease, dermatology based on its company overview and current catalyst commentary.
How does Quoin describe recent progress with Rare?
Completion of Phase 3 recruitment for QRX003 by the end of 2026. Potential NDA submission for QRX003 in 2027.
What is Dermatology?
Rare Dermatology Quoin Pharmaceuticals develops therapies for rare and orphan dermatologic diseases.